Shares of Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT – Get Free Report) dropped 0.2% during trading on Thursday . The company traded as low as $0.12 and last traded at $0.13. Approximately 312,631 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 258,226 shares. The stock had previously closed at $0.13.
Provectus Biopharmaceuticals Stock Down 7.3 %
The company’s fifty day simple moving average is $0.12 and its 200 day simple moving average is $0.11.
Provectus Biopharmaceuticals Company Profile
Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
See Also
- Five stocks we like better than Provectus Biopharmaceuticals
- Insider Trading – What You Need to Know
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- What is a Stock Market Index and How Do You Use Them?
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- Top Biotech Stocks: Exploring Innovation Opportunities
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
